Details

Autor(en) / Beteiligte

• Trabal, Jose F.
• Lenihan, John P.
• Melchione, Thomas E.
• Stoltz, Randall R.
• Khairi, Saeeda
• Yang, Hwa-Ming
• van der Hoop, Roland Gerritsen

Titel

Low-Dose Unopposed Estrogens: Preliminary Findings on the Frequency and Duration of Vaginal Bleeding in Postmenopausal Women Receiving Esterified Estrogens over a Two-Year Period

Ist Teil von

• Menopause (New York, N.Y.), 1997, Vol.4 (3), p.130-138

Ort / Verlag

The North American Menopause Society

Erscheinungsjahr

1997

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• The objective of this study is to compare the frequency and duration of vaginal bleeding in postmenopausal women randomized to receive unopposed esterified estrogens (ESE) in a dose of 0.3 mg, 0.625 mg, 1.25 mg, or placebo. A two-year randomized, double-blind, placebo-controlled, multicenter study was conducted in 269 non-hysterectomized postmenopausal women who recorded bleeding incidence and severity on diary cards. Amenorrhea occurred in 61% of women receiving placebo and 59%, 51%, and 24% of women treated with 0.3, 0.625, and 1.25 mg ESE, respectively. Combining spotting with amenorrhea, these numbers increased to 88%, 88%, 75%, and 61%, respectively. Onset of menopause greater than 1 year before study entry was associated with less bleeding than onset within 1 year (53% vs. 31%). Treatment with 0.3 mg ESE, a dose that is effective in preventing osteoporosis, did not result in a higher incidence of vaginal bleeding or endometrial hyperplasia than treatment with placebo over a 2-year period. Studies longer than 2 years will be needed to confirm that the beneficial effects on bone can occur without any detrimental endometrial effects.